POLYMED - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.5
| Stock Code | POLYMED | Market Cap | 15,327 Cr. | Current Price | 1,512 ₹ | High / Low | 2,938 ₹ |
| Stock P/E | 44.2 | Book Value | 285 ₹ | Dividend Yield | 0.23 % | ROCE | 18.2 % |
| ROE | 14.2 % | Face Value | 5.00 ₹ | DMA 50 | 1,427 ₹ | DMA 200 | 1,700 ₹ |
| Chg in FII Hold | -3.49 % | Chg in DII Hold | 1.76 % | PAT Qtr | 83.4 Cr. | PAT Prev Qtr | 89.0 Cr. |
| RSI | 60.8 | MACD | 44.1 | Volume | 62,003 | Avg Vol 1Wk | 1,26,268 |
| Low price | 1,182 ₹ | High price | 2,938 ₹ | PEG Ratio | 1.43 | Debt to equity | 0.08 |
| 52w Index | 18.8 % | Qtr Profit Var | -2.04 % | EPS | 33.8 ₹ | Industry PE | 38.8 |
📊 Optimal Buy Price (Intraday): ₹1,495–1,515 (near DMA 50 support at ₹1,427)
🎯 Profit-Taking Levels: ₹1,540–1,570 (short-term resistance zone, below DMA 200 at ₹1,700)
🛡️ Stop-Loss / Loss Protection: ₹1,470–1,475 (below intraday support)
⏱️ Exit Strategy (If Already Holding): Exit if price fails to sustain above ₹1,475 with rising volume, or book profits near ₹1,540–1,570 if RSI weakens. Extend trades only if breakout volume sustains above ₹1,570.
---
### Positive
- Strong fundamentals: ROCE 18.2% and ROE 14.2% highlight decent efficiency.
- EPS of ₹33.8 supports earnings visibility.
- PEG ratio at 1.43 indicates reasonable growth-adjusted valuation.
- Debt-to-equity at 0.08 shows low leverage risk.
- Price trading above DMA 50 (₹1,427), confirming short-term support.
### Limitation
- PAT declined sequentially (₹89 Cr. → ₹83.4 Cr.), showing earnings pressure.
- RSI at 60.8 indicates moderate momentum but not strongly bullish.
- MACD at 44.1 shows mild bullish bias but lacks strong breakout signals.
- Current price below DMA 200 (₹1,700), limiting medium-term momentum.
- Volume (62k) below weekly average (126k), showing weaker participation.
### Company Negative News
- FII holding reduced (-3.49%), reflecting foreign investor caution.
- Quarterly profit variation (-2.04%) highlights earnings slowdown.
### Company Positive News
- DII holding increased (+1.76%), supporting sentiment.
- EPS of ₹33.8 provides valuation strength.
- 52-week index at 18.8% shows modest relative performance.
### Industry
- Medical devices sector benefits from rising healthcare demand but faces regulatory and competitive risks.
- Industry PE at 38.8 is lower than POLYMED’s P/E (44.2), highlighting valuation premium.
### Conclusion
POLYMED is a moderate intraday candidate with decent fundamentals and short-term bullish momentum, but valuations remain stretched and earnings have weakened. Best suited for disciplined trades between ₹1,495–1,570 with strict stop-loss at ₹1,475. Avoid aggressive positions unless strong breakout volume confirms strength above ₹1,570; risk remains moderate due to earnings decline and foreign investor caution.
Would you like me to add a sector overlay and peer benchmarking HTML template (Transasia, Opto Circuits, other medical device peers) so you can compare POLYMED’s intraday setup against competitors for workflow clarity?